DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 64
- Registration Number
- NCT05388903
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- Conditions
- Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
- Interventions
- Drug: Platinum-based chemotherapy
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 586
- Registration Number
- NCT05338970
- Locations
- 🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸Highlands Oncology, Springdale, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- Conditions
- Extensive-stage Small-cell Lung Cancer
- Interventions
- Drug: Ifinatamab Deruxtecan (I-DXd)
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 187
- Registration Number
- NCT05280470
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸The Cancer Specialists, Llc, Jacksonville, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- Conditions
- Metastatic Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 740
- Registration Number
- NCT05215340
- Locations
- 🇺🇸
Ironwood Cancer and Research Center, Chandler, Arizona, United States
🇺🇸UCLA HemOnc - Clinical Research Unit, Los Angeles, California, United States
🇺🇸Compassionate Cancer Care Medical Group, Riverside, California, United States
A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 80
- Registration Number
- NCT05203692
- Locations
- 🇺🇸
Apex Clinical Research (Collaborative Neuroscience Research), Long Beach, California, United States
🇺🇸Worldwide Clinical Trials, San Antonio, Texas, United States
An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 3300
- Registration Number
- NCT05120895
- Locations
- 🇰🇷
Soon Chun Hyang University Hospital Bucheon, Bucheon-si, Korea, Republic of
🇰🇷Bucheon Sejong Hospital, Bucheon, Korea, Republic of
🇰🇷Inje University Busan Paik Hospital, Busan, Korea, Republic of
An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes
- Conditions
- Dyslipidemia Associated With Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2972
- Registration Number
- NCT05107063
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷The Catholic University of Korea, Bucheon St. Mary's Hospital, Bucheon, Korea, Republic of
🇰🇷Yeongnam University Medical Center, Busan, Korea, Republic of
Pseudoxanthoma Elasticum (PXE) Natural History Biomarkers in PXE Individuals and Their Biological Non-PXE Siblings
- Conditions
- Pseudoxanthoma Elasticum
- Interventions
- Other: Non Interventional
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 48
- Registration Number
- NCT05025722
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- Drug: 14C-Quizartinib solution for infusion
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 8
- Registration Number
- NCT04796831
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 5000
- Registration Number
- NCT04747496
- Locations
- 🇨🇳
Beijing Tsinghua Changgung Hospital Affiliated Hospital of Tsinghua University, Beijing, Changping District, China
🇨🇳Aviation General Hospital of China Medical University, Beijing, Chaoyang District, China
🇨🇳Beijing Anzhen Hospital, Capital Medical University, Beijing, Chaoyang District, China